
Effects of Acupuncture on Vascular Cognitive Impairment with No Dementia: A Randomized Controlled Trial
Author(s) -
Li Huang,
Xuan Yin,
Wei Li,
Yan Cao,
Yueqi Chen,
Lixing Lao,
Zhangjin Zhang,
Yiqun Mi
Publication year - 2021
Publication title -
journal of alzheimer's disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.677
H-Index - 139
eISSN - 1875-8908
pISSN - 1387-2877
DOI - 10.3233/jad-201353
Subject(s) - montreal cognitive assessment , medicine , acupuncture , randomized controlled trial , dementia , physical therapy , rating scale , clinical dementia rating , mini–mental state examination , vascular dementia , cognition , depression (economics) , adverse effect , psychology , psychiatry , developmental psychology , alternative medicine , disease , pathology , economics , macroeconomics
Background: Acupuncture has been used for treating vascular cognitive impairment, but evidence for its effectiveness remains limited. Objective: This single-center, patient-accessor blinded, randomized controlled trial was designed to assess whether acupuncture could improve the cognitive function of patients with vascular cognitive impairment with no dementia (VCIND). Methods: 120 VCIND patients were randomly assigned to the electro-acupuncture (EA) or sham acupuncture (SA) group at a 1 : 1 ratio, with treatment conducted thrice weekly for 8 weeks. The primary outcome was the changes of cognitive function measured by the Montreal Cognitive Assessment (MoCA) from baseline to week 8. The secondary outcomes included the scores of the Mini-Mental State Examination (MMSE), the Modified Barthel Index (MBI) and the Self-rating Depression Scale (SDS). Follow-up assessments were performed with MoCA and MMSE at week 16 and 32. Linear mixed-effects models were used for analysis and all statistical tests were two-sided. Results: The results showed that patients in the EA group had a significantly greater improvement in MoCA score (23.85±4.18) than those in the SA group (21.48±4.44) at week 8 (95% CI = 0.80, 3.92, p = 0.04), as well as higher MoCA scores over time (p < 0.001 for interaction). Patients who received EA showed a greater increase in MMSE scores (26.41±3.47) than those who received SA (24.40±3.85) along 8 weeks (95% CI = 0.69, 3.34, p = 0.004). However, results diminished over time. No serious adverse events occurred during the trial. Conclusion: EA is a safe and effective technique to improve cognition over the short term of 8 weeks in VCIND patients.